Cargando…
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
BACKGROUND/AIMS: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. METHODS:...
Autores principales: | Woo, Hyun Young, Park, Jun Yong, Bae, Si Hyun, Kim, Chang Wook, Jang, Jae Young, Tak, Won Young, Kim, Dong Joon, Kim, In Hee, Heo, Jeong, Ahn, Sang Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364362/ https://www.ncbi.nlm.nih.gov/pubmed/32460460 http://dx.doi.org/10.3350/cmh.2019.0044n |
Ejemplares similares
-
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015) -
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
por: Kim, Jeong Han, et al.
Publicado: (2016) -
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015) -
Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
por: Ze, EunYoung, et al.
Publicado: (2014) -
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)